CEOCFO magazine interview with Machavert Pharmaceuticals CEO, Dr. Jakub Staszak-Jirkovsky
AURORA, Colo., Feb. 13, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, was featured in an interview by CEOCFO magazine. The article with the title: "Developing the first Drug Candidates based on Phospholipid that Activates Natural Killer Cells, Machavert Pharmaceuticals is leading the way in this new approach of Harnessing the Power of the Human Body to Fight Against Cancer" was published on February 11, 2019 and brings in-depth interview between the CEO of Machavert, Dr. Jakub Staszak-Jirkovsky and the senior editor Lynn Fosse.
The interview focused on core technologies currently developed at Machavert and their possible impact on treatment of cancer. Namely, the novel way to activate the Natural Killer cells to attack cancer and the expected synergy with already successful immunotherapies was highlighted. Also discussed was the feasibility to combine this approach with other therapeutics and the focus of Machavert to diversify the portfolio of drug candidates that bring a novel and unique way to tackle cancers that are currently very difficult to treat. Further, the importance of assembling a dedicated expert team was addressed as well as general strategy to make a small company with a very novel and ambitious project visible and attractive to potential partners and investors. The full interview can be accessed here: https://www.ceocfointerviews.com/interviews/MachavertPharmaceuticals19.htm
About Machavert Pharmaceuticals
Machavert Pharmaceuticals is a preclinical stage drug development company focused on advanced therapies based on its proprietary bioactive phospholipid platform for the treatment of multiple cancers in hematology and solid tumor oncology. The phospholipid platform is also being combined with other therapeutics such as small molecules for precision medicine and immuno-oncology. Machavert's core focus is on difficult-to-treat driver mutations and other orphan indications in oncology.
For further information: Jakub Staszak-Jirkovsky, Chief Executive Officer, Machavert Pharmaceuticals, 720.859.4048, email@example.com
SOURCE Machavert Pharmaceuticals